![](/img/cover-not-exists.png)
227P Phase II study of pembrolizumab (pembro) plus enzalutamide for enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update from KEYNOTE-199
Vaishampayan, U.N., Elliott, T., Omlin, A.G., Graff, J.N., Hoimes, C.J., Tagawa, S.T., Hwang, C., Kilari, D., Tije, A.J. Ten, McDermott, R.S., Gerritsen, W.R., Wu, H., Kim, J., Schloss, C., de Bono, JVolume:
31
Journal:
Annals of Oncology
DOI:
10.1016/j.annonc.2020.10.447
Date:
November, 2020
File:
PDF, 86 KB
2020